Katrine Bosley joined Editas Medicine as president and chief executive officer in 2014, shortly after the company was founded. Katrine has been part of the biotechnology industry for over 25 years. Before Editas, she was entrepreneur–in–residence at The Broad Institute, a biomedical and genomic research center, and prior to that, she was president and CEO of Avila Therapeutics. Earlier, Katrine was vice president, Business Development at Adnexus Therapeutics, and she held several positions at Biogen in business development, commercial operations, and portfolio strategy. She was also part of the health care team at the venture firm Highland Capital Partners. She is a graduate of Cornell University.
In addition to her role at Editas, Katrine currently serves as chairman of the board of Genocea Biosciences (NASDAQ: GNCA) and is a member of the board of directors of Galapagos NV (EURONEXT and NASDAQ:GLPG), of BIO – the Biotechnology Innovation Organization, and of Massachusetts Eye and Ear.